Autonomix Medical reports Q1 FY2025 net loss $2.7M, positive 7-day pain relief data from lead-in patients

Autonomix Medical, Inc.

Net loss $2.7M vs $0.9M YoY; cash $6.8M as of June 30, 2024.
G&A $1.8M (up $1.3M) and R&D $1.0M (up $0.6M) driven by compensation and clinical costs.
60% of first five lead-in patients had mean 6.33 VAS pain reduction (from 8.0 to 1.67) at 7 days.
Appointed Brad Hauser CEO; licensed RF Innovations' FDA-cleared Apex 6 ablation generator.
Expects topline PoC trial data 1H CY2025, FDA de novo submission 2026, clearance 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.